Trials / Completed
CompletedNCT00977665
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 174 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rasagiline mesylate | rasagiline 1 mg tablet/day for 48 weeks |
| DRUG | placebo | placebo tablet for 48 weeks |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-09-16
- Last updated
- 2015-02-26
- Results posted
- 2015-02-26
Locations
47 sites across 12 countries: United States, Austria, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00977665. Inclusion in this directory is not an endorsement.